Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.13066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Thomas C Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Leukemia, Dog Diseases, Antineoplastic Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NeOnc Technologies, Inc..
Abstract (Originalsprache)
Haematological cancer types, such as leukaemia and lymphoma, represent diseases that are life‐threatening to canine and human patients alike, and better treatments are needed. We are developing a novel anticancer agent, NEO212, a conjugate of two cancer drugs, the alkylating agent temozolomide (TMZ) and the monoterpene perillyl alcohol (POH). NEO212 has revealed robust therapeutic activity in preclinical tumour models harbouring different human cancer types. In the comparative preclinical study presented here, a two‐species (canine and human) and two‐cancer (leukaemia and lymphoma) analysis was performed to determine whether the promising therapeutic activity of NEO212 would span species and cancer types. We investigated the activity of NEO212 in human and canine leukaemia and lymphoma cell lines in vitro and in corresponding mouse models in vivo. Our results show that in vitro NEO212 is significantly more potent than TMZ and POH in all cell lines and exerts activity even against strongly TMZ‐resistant tumour cells. In vivo, oral NEO212 strikingly extends the survival of mice harbouring human or canine leukaemia or lymphoma cells. At the same time, NEO212 is well tolerated in dogs at dosages higher than those that achieved therapeutic activity in mouse models. Our study introduces NEO212 as a novel oral cancer drug candidate for both human and veterinary oncology applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA.
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, USA.
- NeOnc Technologies, Inc., Westlake Village, California, USA.
- Department of Molecular Microbiology and Immunology, Keck School of Medicine, USC, Los Angeles, California, USA.
ORCID-Profile: Thomas C Chen, Steve Swenson, Radu O Minea, Axel H Schönthal
Förderung
- NCI NIH HHS
- NeOnc Technologies, Inc.
Zitieren
APA
Chen, T. C., Swenson, S., Thein, T. Z., Minea, R. O., & Schönthal, A. H. (2025). Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13066
Vancouver
Chen TC, Swenson S, Thein TZ, Minea RO, Schönthal AH. Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.13066
BibTeX
@article{Chen2025,
author = {Chen, Thomas C and Swenson, Steve and Thein, Thu Zan and Minea, Radu O and Schönthal, Axel H},
title = {Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.13066}
}
EUVIMED